头孢地嗪的临床及免疫调节作用研究

CLINICAL EVALUATION AND IMMUNOMODULATORY STUDY OF CEFODIZIME

为评价头孢地嗪治疗免疫缺陷者感染的疗效、安全性及免疫调节作用，在１０７例呼吸道、尿路及其他细菌感染中，与头孢唑肟进行随机对照研究。有效率、痊愈率和细菌清除率头孢地嗪组分别为８７．３％、６１．８％和８９．３％；头孢唑肟组分别为８２．７％、５９．６％和９０．６％。不良反应发生率头孢地嗪组５．２％，头孢唑肟组７．４％。头孢地嗪组治疗后ＣＤ＋４、ＣＤ＋４／ＣＤ＋８比值升高，ＮＫ细胞活性增强，活化的淋巴细胞白细胞介素－２受体表达增多，对照药头孢唑肟则无显著作用。研究结果显示，头孢地嗪治疗免疫缺陷者感染安全有效，并具免疫调节作用。

To investigate the efficacy, safety and immunomodulating activities of cefodizime in immunocompromised patients with infections, we carried out a randomized controlled prospective study of cefodizime vs ceftizoxime in 107 patients. The total effective cure rate and bacterial eradication rate were 87.3%, 61.8% and 89.3% in cefodizime group and 82.7%, 59.6% and 90.6% in ceftizoxime group. Drug tolerence was similar in the two groups, and side effect was mild and transient, mainly gastrointestinal reactions. Cefodizime had effect on both phagocyte and lymphocyte functions: enhancing the phagocytie rate, phagocytic index and bacterial killing activity, increasing the number of CD+4 lymphacyte and the ratio of CD+4/CD+8, stimulating NK cell activity and enhancing expression of IL2R of active lymphocyte. Meanwhile ceftizoxime had no effect on any of the parameter mentioned above. The result showed that cefodizime is effective and safe in the treatment of LRTI, upper and complicated UTI in immunocompromised patients, as well as possessed immunomodulating activities.